Endothelial cell function and thrombosis.

The endothelium is pivotal in the control of haemostasis and thrombosis because it is the primary source of many of the major haemostatic regulatory molecules. Healthy endothelial cells, unlike extravascular cells, are anticoagulant and antithrombotic. This is due to the regulated secretion of antiplatelet agents, including prostacyclin and nitric oxide. Following vessel injury, platelet adhesion to exposed matrix requires von Willebrand Factor, another endothelial cell product. Local generation of thrombin causes a series of receptor-mediated endothelial cell functional responses, while the surface of the endothelium is additionally the site for inactivation of thrombin by antithrombin, and its conversion to a coagulation inhibitor by interaction with thrombomodulin. Endothelial cells are also the source of circulating tissue-type plasminogen activator and its inhibitor, and Tissue Factor pathway inhibitor. In disease states, many of these endothelial cell properties are perturbed towards a more procoagulant and prothrombotic phenotype.

[1]  J. Emeis The Control of tPA and PAI-1 Secretion from the Vessel Wall , 1995 .

[2]  J. Pearson,et al.  von Willebrand factor is an acute phase reactant in man. , 1989, Thrombosis research.

[3]  S. Rapaport,et al.  Studies of the Factor Xa-Dependent Inhibitor of Factor VIIa/Tissue Factor (Extrinsic Pathway Inhibitor) from Cell Supernates of Cultured Human Umbilical Vein Endothelial Cells , 1989, Thrombosis and Haemostasis.

[4]  D. Wagner Cell biology of von Willebrand factor. , 1990, Annual review of cell biology.

[5]  K. Hajjar Cellular Receptors in the Regulation of Plasmin Generation , 1995, Thrombosis and Haemostasis.

[6]  C. Esmon,et al.  Identification, cloning, and regulation of a novel endothelial cell protein C/activated protein C receptor. , 1994, The Journal of biological chemistry.

[7]  K Fujikawa,et al.  The coagulation cascade: initiation, maintenance, and regulation. , 1991, Biochemistry.

[8]  A. K. Pedersen,et al.  Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. , 1984, The New England journal of medicine.

[9]  D. Crossman,et al.  The regulation of tissue factor mRNA in human endothelial cells in response to endotoxin or phorbol ester. , 1990, The Journal of biological chemistry.

[10]  H. Friedman,et al.  Viral activation of the coagulation cascade: Molecular interactions at the surface of infected endothelial cells , 1990, Cell.

[11]  J. Pearson,et al.  Vessel wall interactions regulating thrombosis. , 1994, British medical bulletin.

[12]  R. Derksen,et al.  Synergistic Effect of Low Doses of Tumor Necrosis Factor and Sera from Patients with Systemic Lupus Erythematosus on the Expression of Procoagulant Activity by Cultured Endothelial Cells , 1989, Thrombosis and Haemostasis.

[13]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[14]  J. Moake,et al.  Thrombotic thrombocytopenic purpura and the haemolytic-uraemic syndrome: evolving concepts of pathogenesis and therapy. , 1986, Clinics in haematology.

[15]  J. Cooke,et al.  Arginine Restores Cholinergic Relaxation of Hypercholesterolemic Rabbit Thoracic Aorta , 1991, Circulation.

[16]  S. Moncada,et al.  Comparative pharmacology of endothelium‐derived relaxing factor, nitric oxide and prostacyclin in platelets , 1987, British journal of pharmacology.

[17]  S Moncada,et al.  Role of endothelium-derived nitric oxide in the regulation of blood pressure. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[18]  H. Saito,et al.  Cultured normal human hepatocytes do not synthesize lipoprotein-associated coagulation inhibitor: evidence that endothelium is the principal site of its synthesis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[19]  H. Niwano,et al.  Circulating thrombomodulin as a novel endothelial cell marker: Comparison of its behavior with von willebrand factor and tissue‐type plasminogen activator , 1992, American journal of hematology.

[20]  E. Bjørklid,et al.  Production and availability of thromboplastin in endothelial cells: the effects of thrombin, endotoxin and platelets , 1984, British journal of haematology.

[21]  A. Marcus,et al.  Inhibition of platelet function by an aspirin-insensitive endothelial cell ADPase. Thromboregulation by endothelial cells. , 1991, The Journal of clinical investigation.

[22]  T. Carter,et al.  Regulation of Prostacyclin Synthesis in Endothelial Cells , 1992 .

[23]  D. Fass,et al.  Transplantation of normal bone marrow into a pig with severe von Willebrand's disease. , 1986, The Journal of clinical investigation.

[24]  W. Kisiel,et al.  Tumor necrosis factor-induced endothelial tissue factor is associated with subendothelial matrix vesicles but is not expressed on the apical surface , 1992 .

[25]  G. Zimmerman,et al.  Cultured endothelial cells synthesize both platelet-activating factor and prostacyclin in response to histamine, bradykinin, and adenosine triphosphate. , 1985, The Journal of clinical investigation.

[26]  F. Siddiqui,et al.  Binding of Platelet Agglutinating Protein p 37 from the Plasma of a Patient with Thrombotic Thrombocytopenic Purpura to Human Platelets , 1991, Thrombosis and Haemostasis.

[27]  K. Nagai,et al.  Inhibitory effects of TTP sera on binding of anti‐platelet glycoprotein IIb‐IIIa monoclonal antibodies to human vascular endothelial cells , 1987, American journal of hematology.

[28]  S. Moncada EIGHTH GADDUM MEMORIAL LECTURE UNIVERSITY OF LONDON INSTITUTE OF EDUCATION DECEMBER 1980: BIOLOGICAL IMPORTANCE OF PROSTACYCLIN , 1982, British journal of pharmacology.

[29]  K. Amano,et al.  Fluctuations in Plasma Levels of Thrombomodulin in Patients with DIC , 1992, Thrombosis and Haemostasis.

[30]  G. Remuzzi,et al.  Renal prostacyclin biosynthesis is reduced in children with hemolytic-uremic syndrome in the context of systemic platelet activation. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[31]  T. Ohka,et al.  Changes in plasma levels of thrombomodulin during haemodialysis. , 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[32]  E. Nabel,et al.  Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. , 1990, Journal of the American College of Cardiology.

[33]  T. Lyberg,et al.  Cellular cooperation in endothelial cell thromboplastin synthesis , 1983, British journal of haematology.

[34]  S Moncada,et al.  The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. , 1987, Biochemical and biophysical research communications.

[35]  V. Wheaton,et al.  Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation , 1991, Cell.

[36]  P. Mannucci,et al.  von Willebrand factor: a marker of endothelial damage? , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[37]  J. Marcum,et al.  Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. , 1984, The Journal of clinical investigation.

[38]  T. van der Poll,et al.  Fibrinolytic response to tumor necrosis factor in healthy subjects , 1991, The Journal of experimental medicine.

[39]  P. Ganz,et al.  Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. , 1986, The New England journal of medicine.

[40]  D. Cines,et al.  Antibody and immune complexes induce tissue factor production by human endothelial cells. , 1986, Journal of immunology.

[41]  D. Loskutoff The Biochemistry, Cell and Molecular Biology of Type 1 Plasminogen Activator Inhibitor , 1991 .

[42]  J. V. van Mourik,et al.  Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. , 1990, Journal of immunology.

[43]  S. Tannenbaum,et al.  Immune endothelial-cell injury in heparin-associated thrombocytopenia. , 1987, The New England journal of medicine.

[44]  H. Drexler,et al.  Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. , 1991, Circulation.

[45]  P. Vanhoutte,et al.  Flow-induced release of endothelium-derived relaxing factor. , 1986, The American journal of physiology.

[46]  G. Zimmerman,et al.  Endothelial cell-associated platelet-activating factor: a novel mechanism for signaling intercellular adhesion , 1990, The Journal of cell biology.

[47]  J. Kelton,et al.  Calpain proteolysis of von Willebrand factor enhances its binding to platelet membrane glycoprotein IIb/IIIa: an explanation for platelet aggregation in thrombotic thrombocytopenic purpura , 1990, British journal of haematology.

[48]  A. Marcus,et al.  Synthesis of prostacyclin from platelet-derived endoperoxides by cultured human endothelial cells. , 1980, The Journal of clinical investigation.

[49]  J. Soria,et al.  Effect of Lupus Anticoagulant on Antithrombogenic Properties of Endothelial Cells - Inhibition of Thrombomodulin-Dependent Protein C Activation , 1988, Thrombosis and Haemostasis.

[50]  V. Hinsbergh Regulation of the synthesis and secretion of plasminogen activators by endothelial cells. , 1988, Haemostasis.

[51]  J. Pearson Autoantibodies to Endothelial Cells , 1991 .

[52]  D. Moscatelli,et al.  The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells , 1987, The Journal of cell biology.

[53]  S. Rapaport,et al.  Disseminated intravascular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. , 1990, Blood.

[54]  M. Shuman,et al.  Characterization of the effects of cultured vascular cells on the activation of blood coagulation. , 1983, Blood.

[55]  R. Derksen,et al.  8 Antiphospholipid antibodies: Specificity and pathophysiology , 1993 .

[56]  H. Gerlach,et al.  Hypoxia modulates the barrier and coagulant function of cultured bovine endothelium. Increased monolayer permeability and induction of procoagulant properties. , 1990, The Journal of clinical investigation.

[57]  M. Gimbrone,et al.  Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. , 1988, The Journal of biological chemistry.

[58]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[59]  W. Williams,et al.  Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. , 1987, Circulation.

[60]  C. Dollery,et al.  Prostacyclin is not a circulating hormone in man. , 1982, Prostaglandins.

[61]  D. Crossman,et al.  Differential regulation by cytokines of constitutive and stimulated secretion of von Willebrand factor from endothelial cells. , 1990, Blood.

[62]  G. Roth,et al.  Developing relationships: arterial platelet adhesion, glycoprotein Ib, and leucine-rich glycoproteins. , 1991, Blood.

[63]  C. Esmon Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[64]  T. Rink,et al.  Single stretch-activated ion channels in vascular endothelial cells as mechanotransducers? , 1987, Nature.

[65]  J. Paramo,et al.  Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. , 1985, The Journal of clinical investigation.

[66]  J. Pearson The control of production and release of haemostatic factors in the endothelial cell. , 1993, Bailliere's clinical haematology.

[67]  M. Stemerman,et al.  Tissue-factor coagulant activity of cultured human endothelial and smooth muscle cells and fibroblasts , 1977 .

[68]  M J Davies,et al.  A macro and micro view of coronary vascular insult in ischemic heart disease. , 1990, Circulation.

[69]  J. Pearson,et al.  Nucleotide metabolism by endothelium. , 1985, Annual review of physiology.

[70]  R. Cotran,et al.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.

[71]  J. Pearson,et al.  Vascular damage in Wegener's granulomatosis and microscopic polyarteritis: presence of anti‐endothelial cell antibodies and their relation to anti‐neutrophil cytoplasm antibodies , 1991, Clinical and experimental immunology.

[72]  P. Woo,et al.  Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. , 1988, Clinical and experimental immunology.

[73]  S. Moncada,et al.  Nitric oxide: physiology, pathophysiology, and pharmacology. , 1991, Pharmacological reviews.

[74]  Tatsuya Hayashi,et al.  Plasma thrombomodulin as a marker of vascular disorders in thrombotic thrombocytopenic purpura and disseminated intravascular coagulation , 1992, American journal of hematology.

[75]  J. Pearson,et al.  Stimulation of prostaglandin production through purinoceptors on cultured porcine endothelial cells. , 1983, The Biochemical journal.

[76]  G. Schernthaner,et al.  The effect of near-normoglycemic control on plasma factor VIII/von Willebrand factor and fibrin degradation products in insulin-dependent diabetic patients. , 1989, The Journal of clinical endocrinology and metabolism.

[77]  P. Sandset,et al.  Extrinsic pathway inhibitor--the key to feedback control of blood coagulation initiated by tissue thromboplastin. , 1991, Haemostasis.